Europska Unija - hrvatski - EMA (European Medicines Agency)

sandoz gmbh - pregabalin - anxiety disorders; epilepsy - antiepileptici sredstva, - epilepsypregabalin Сандоз gmbh prikazan kao dodatna terapija kod osoba s парциальными судорогами sa ili bez sekundarne generalizacije. postati generalizirani anksioznosti disorderpregabalin Сандоз gmbh je indiciran za liječenje generalizirani anksiozni poremećaj (gap) kod odraslih.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - adalimumab - otopina za injekciju u napunjenoj štrcaljki - 40 mg/0.8 ml - 1 ml otopine za injekciju u napunjenoj štrcaljki sadrži: 50 mg adalimumaba

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - adalimumab - otopina za injekciju u napunjenoj štrcaljki - 20 mg/0.4 ml - 1 ml otopine za injekciju u napunjenoj štrcaljki sadrži: 50 mg adalimumaba

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - adalimumab - rastvor za injekciju u napunjenom penu - 40 mg/0.8 ml - 1ml otopine za injekciju u napunjenom penu sadrži: 50 mg adalimumaba

Europska Unija - hrvatski - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - imunosupresivi - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. tretman teških, aktivnog i uznapredovalog reumatoidnog artritisa kod odraslih, ne ranije liječenih metotreksat. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšava fizičke funkcije, imenovanje u kombinaciji s metotreksatom. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično (na učinkovitost u monoterapija vidi odjeljak 5. Адалимумаб ne ima dugu povijest u bolesnika u dobi od manje od 2 godine. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita smanjuje brzinu progresije periferne lezije zgloba, mjereno pomoću x-zraka u bolesnika s полиартикулярным mogućnost simetrične podtipovi bolesti (vidi odjeljak 5. 1) i poboljšava fizičke značajke. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 i 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

teva gmbh, graf-arco-str. 3, ulm, njemačka - dimetilfumarat - Želučanootporna kapsula, tvrda - urbroj: jedna tvrda želučanootporna kapsula sadrži 120 mg dimetilfumarata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

teva gmbh, graf-arco-str. 3, ulm, njemačka - dimetilfumarat - Želučanootporna kapsula, tvrda - urbroj: jedna tvrda želučanootporna kapsula sadrži 240 mg dimetilfumarata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ferring gmbh, wittland 11, kiel, njemačka - triptorelinacetat - prašak i otapalo za suspenziju za injekciju - 3,75 mg - urbroj: 1 napunjena štrcaljka s praškom sadrži 3,75 mg triptorelinacetata (1 ml pripremljene suspenzije sadrži 3,69 mg triptorelinacetata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - mcloksikam - oxicams - psi - olakšanje upala i bolova u akutni i kronični mišićno-koštanog sustava u pasa.

Europska Unija - hrvatski - EMA (European Medicines Agency)

archie samiel s.r.o. - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - Клопидогрел prikazan odrasle za prevenciju атеротромботических događaja:pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija;u bolesnika koji pate od akutne коронарным sindroma:bez st-segment visina akutni koronarni sindromi (nestabilnom anginom ili bez trn q infarkt miokarda), uključujući i bolesnike koji su patili стентирование nakon чрескожного koronarne intervencije, u kombinaciji s ацетилсалициловой kiselinom (ask);segment st-visina infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije.